Laboratoire Francais Du Fractionnement Et Des Biotechnologies

Institut National De La Sante Et De La Recherche Medicale

Universitè De Montpellier

Centre National De Lutte Contre Le Cancer

Other

Lfb Biotechnologies

Etat Francais Represente Par Le Delegue General De L'armement

Etat Francais Represente Par Le Directeur Central Du Service De Sante Des Armees

Mab Factory Gmbh

Etat Francais Represente Par Le Delegue General Pour L'armement

Christian Behrens

Sylvie Jorieux

Philippe Mondon

Abdelhakim Kharrat

Khalil Bouayadi

Celine Monnet-Mars

Jean-Marie Saint-Remy

Christophe De Romeuf

Marc G Jacquemin

Isabelle Navarro-Teulon

Christine Gaucher

Lars Toleikis

Philippe Klein

Stefan Dübel

Michael Hust

Holger Thie

Philippe Thullier

Jean Guy Gilles

Denis Hoguet

Thomas Schirrmann

Jean-Guy Gilles

Céline Monnet-Mars

Jean-Marie R Saint-Remy

The present invention relates to a class-G immunoglobulin against the anthrax toxin protective antigen (PA), or one of the fragments of same, comprising at least: a variable heavy-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 1, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 1, and comprising the amino acids Leucine in position 51 and Glycine in position 67, and a variable light-chain region comprising an amino acid sequence represented by the sequence SEQ ID NO: 2, or comprising an amino acid sequence having at least 90% identity with the sequence SEQ ID NO: 2, and comprising a Leucine amino acid in position 55. The invention also relates to the uses of such an immunoglobulin.

Immunoglobulin against the anthrax toxin

A variant of a parent polypeptide including an Fc region, which variant exhibits increased binding to FcRn as compared to the parent polypeptide and includes at least one amino acid modification in the Fc region.

Optimized FC variants

Novel mutated humanized 12G4 antibodies, and fragments thereof, directed against the anti-M&#xfc;llerian hormone type II receptor.

Mutated humanized 12G4 antibodies and the fragments thereof against the human anti-Mullerian hormone receptor type II

Antibodies having a high specificity and high affinity towards the human gene product MUC1, which in specific variants is associated with neoplastic cells, i.e. tumor tissue, to the use of the antibodies for medical purposes, i.e. for tumor treatment, and for analytical purposes, e.g. for tumor diagnosis. Compositions comprising the antibodies, e.g. for use in the analytical processes and analysis, to pharmaceutical compositions comprising the antibodies, and to use of the antibodies in the manufacture of pharmaceutical compositions for tumor treatment or for diagnostic purposes.

Recombinant anti-MUC1 antibodies

An immunoglobulin of the G class (IgG) directed against the protective antigen (PA) of the anthrax toxin, includes:

G immunoglobulin used against anthrax toxins

The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the C1 domain of Factor VIII, as well as to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as medicament, and more particularly to the use thereof for manufacturing a medicament intended for the treatment of haemophilia A.

Anti-idiotypic antibodies neutralizing the inhibitory activity of an inhibitory antibody directed against the C1 domain of Factor VIII

The present invention is related to a monoclonal anti-idiotypic antibody directed against a Factor VIII inhibitor antibody binding to the domain A2 of Factor VIII, and to a cell line producing this monoclonal anti-idiotypic antibody, to the use of this monoclonal anti-idiotypic antibody as drug, and more particularly, to its use for the manufacturing of a drug to be used for the treatment of haemophilia A.

Anti-idiotypic antibody neutralizing the inhibitor activity of a factor VIII inhibitor antibody

The invention relates to an anti-idiotypical antibody targeting an antibody inhibiting the human factor VIII, said inhibiting antibody targeting the C2 region of the human factor VIII, the variable region of each of the light chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 1, and the variable region of each of the heavy chains thereof being encoded by a sequence of nucleic acids of which at least 70% is identical to the murine sequence of nucleic acids SEQ ID NO: 2, the constant regions of the light chains and the heavy chains being constant regions from a non-murine species. The invention also relates to the use of said antibody for activating the Fc&#x3b3;RIII receptors of cytotoxic immune cells, and to the production of a medicament especially for the treatment of haemophilia A.

Cytotoxic antibodies directed against antibodies inhibiting factor VIII

Growing community of inventors

Palaiseau, France

Christian Behrens